MRI-Based Predictors of Treatment Failure in Intermediate-Risk Prostate Cancer Treated With High-Dose-Rate Brachytherapy as Monotherapy

Authors

Jacob E. Oyeniyi, Corewell Health East Resident
Joseph S. Lee, Corewell Health East Resident
Chen Shen, Corewell Health East
Bailey A. Loving, Corewell Health East Resident
Sirisha R. Nandalur, Corewell Health East
Andrew B. Thompson, Corewell Health East
Kiran R. Nandalur, Corewell Health East
Zachary A. Seymour, Corewell Health East
Evelyn L. Sebastian, Corewell Health East
Amy Limbacher, Corewell Health East
Daniel J. Krauss, Corewell Health East

Document Type

Conference Proceeding

Publication Date

7-2025

Publication Title

Brachytherapy

Volume

24

Issue

4 Suppl

First Page

S13

Last Page

S13

Recommended Citation

Oyeniyi JF, Lee JS, Shen C, Loving BA, Nandalur SR, Thompson AB. et al. [Nandalur KR, Seymour ZA, Sebastian EL, Limbacher A, Krauss DJ]. MRI-based predictors of treatment failure in intermediate-risk prostate cancer treated with high-dose-rate brachytherapy as monotherapy. Brachytherapy. 2025 Jul-Aug;24(4 Suppl):S13. doi:10.1016/j.brachy.2025.06.020

Comments

American Brachytherapy Society Annual Conference, June 18-21, 2025, Nashville, TN

DOI

10.1016/j.brachy.2025.06.020